Computer Tool for Colorectal Liver Metastasis Treatment
Multi-Reader Multi-Case Trial Evaluating Computer-Aided Tool for Prognostic Prediction of Colorectal Liver Metastases
Recruiting
Observational Study
Colorectal Liver Metastasis (CRLM)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
166 (estimated)
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Other
Who this trial is looking for
This trial is looking for adults with liver metastases from colorectal cancer who are having surgery to remove both the cancer in the colon and the liver tumors. Participants will help researchers see if a new computer tool can better predict outcomes after surgery.
Are You a Good Fit for This Trial?
You may be able to join if
I am 18 years or older
I have liver metastases from colorectal adenocarcinoma
I am receiving surgery for colorectal resection and simultaneous liver resection
You may not be able to join if
I have other types of cancer
I do not have follow-up data
I was followed up for less than 5 years and did not experience death
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
This study evaluates the impact of a novel computer-aided prognostic prediction tool for colorectal liver metastases (CRLM) on clinician performance. Colorectal cancer is a leading cause of cancer-related mortality worldwide, with 20-30% of patients presenting synchronous liver metastases, which are associated with poor prognosis and high postoperative recurrence rates. Simultaneous resection of p…
This study evaluates the impact of a novel computer-aided prognostic prediction tool for colorectal liver metastases (CRLM) on clinician performance. Colorectal cancer is a leading cause of cancer-related mortality worldwide, with 20-30% of patients presenting synchronous liver metastases, which are associated with poor prognosis and high postoperative recurrence rates. Simultaneous resection of primary tumor and liver metastases is a preferred treatment for selected patients but outcomes vary significantly. The latest web-based tool uses Random Forest models integrating demographic, clinical, laboratory, and genetic data to predict postoperative recurrence and mortality specifically for CRLM patients undergoing simultaneous resection. This multiple-reader, multiple-case (MRMC) study will assess 12 physicians who will predict 1-, 3-, and 5-year recurrence and mortality risks in 166 retrospective cases, with and without the tool's aid, separated by a washout period. The primary focus is to determine whether the tool improves prediction accuracy for 3-year postoperative mortality, measured by AUC-ROC. Secondary and exploratory endpoints include other time points, sensitivity, specificity, inter-rater reliability, decision-making confidence, and evaluation time. By enabling individualized risk assessment, this tool aims to support optimized clinical decision-making and tailored treatment strategies for CRLM patients undergoing simultaneous resection.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* ≥ 18 years old
* confirmation of histologically diagnosed liver metastases of colorectal adenocarcinoma
* receiving colorectal resection with simultaneous liver resection.
Exclusion Criteria:
* presence of other malignancies
* absence of follow-up data
* patients who were fo…
Inclusion Criteria:
* ≥ 18 years old
* confirmation of histologically diagnosed liver metastases of colorectal adenocarcinoma
* receiving colorectal resection with simultaneous liver resection.
Exclusion Criteria:
* presence of other malignancies
* absence of follow-up data
* patients who were followed up postoperatively for less than 5 years and had no occurrences of death.
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.